Elicio Therapeutics (ELTX) Share-based Compensation (2020 - 2026)
Elicio Therapeutics posted quarterly Share-based Compensation of $868000.0 for Q1 2026, up 67.89% year-on-year from $517000.0 in Q1 2025, and up 12.44% on a QoQ basis from $772000.0 in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of Share-based Compensation data on file, last reported at $868000.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 67.89% year-over-year to $868000.0; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (up 85.29% YoY), and the FY2025 full-year result was $2.7 million, up 85.74% from the prior year.
- Share-based Compensation for Q1 2026 stood at $868000.0, up from $772000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $868000.0 in Q1 2026 and bottomed at $31000.0 in Q1 2022.
- The 5-year median for Share-based Compensation is $337000.0 (2023), against an average of $398529.4.
- The widest annual swing landed in 2022, when Share-based Compensation sank 99.39%; it then soared 622.58% in 2023.
- A 5-year view of Share-based Compensation shows it stood at $199000.0 in 2022, then surged by 69.35% to $337000.0 in 2023, then soared by 37.69% to $464000.0 in 2024, then surged by 66.38% to $772000.0 in 2025, then grew by 12.44% to $868000.0 in 2026.
- The last three Share-based Compensation figures came in at $868000.0 (Q1 2026), $772000.0 (Q4 2025), and $698000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | 868,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 868,000.00 |
| Mar 31, 2026 | 868,000.00 |
| Dec 31, 2025 | 772,000.00 |
| Dec 31, 2025 | 772,000.00 |
| Sep 30, 2025 | 698,000.00 |
| Sep 30, 2025 | 698,000.00 |
| Jun 30, 2025 | 710,000.00 |
| Jun 30, 2025 | 710,000.00 |
| Mar 31, 2025 | 517,000.00 |
| Mar 31, 2025 | 517,000.00 |
| Dec 31, 2024 | 464,000.00 |
| Dec 31, 2024 | 464,000.00 |
| Sep 30, 2024 | 314,000.00 |
| Sep 30, 2024 | 314,000.00 |
| Jun 30, 2024 | 350,000.00 |
| Jun 30, 2024 | 350,000.00 |
| Mar 31, 2024 | 324,000.00 |
| Mar 31, 2024 | 324,000.00 |
| Dec 31, 2023 | 337,000.00 |
| Dec 31, 2023 | 337,000.00 |
| Sep 30, 2023 | 339,000.00 |
| Sep 30, 2023 | 339,000.00 |
| Jun 30, 2023 | 279,000.00 |
| Jun 30, 2023 | 279,000.00 |
| Mar 31, 2023 | 224,000.00 |
| Mar 31, 2023 | 224,000.00 |
| Dec 31, 2022 | 199,000.00 |
| Dec 31, 2022 | 199,000.00 |
| Sep 30, 2022 | 110,000.00 |
| Sep 30, 2022 | 110,000.00 |
| Jun 30, 2022 | 239,000.00 |
| Jun 30, 2022 | 239,000.00 |
| Mar 31, 2022 | 31,000.00 |
| Mar 31, 2022 | 31,000.00 |
| Dec 31, 2021 | 2.02 Mn |
| Dec 31, 2021 | 2.02 Mn |
| Sep 30, 2021 | 2.18 Mn |
| Sep 30, 2021 | 2.18 Mn |
| Jun 30, 2021 | 2.72 Mn |
| Jun 30, 2021 | 2.72 Mn |
| Mar 31, 2021 | 5.12 Mn |
| Mar 31, 2021 | 5.12 Mn |
| Dec 31, 2020 | 1.16 Mn |
| Dec 31, 2020 | 1.16 Mn |
| Sep 30, 2020 | 1.63 Mn |
| Sep 30, 2020 | 1.63 Mn |
| Jun 30, 2020 | 1.10 Mn |
| Jun 30, 2020 | 1.10 Mn |
| Mar 31, 2020 | 832,000.00 |
| Mar 31, 2020 | 832,000.00 |